Tokio Marine Asset Management Co. Ltd. Decreases Position in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Tokio Marine Asset Management Co. Ltd. reduced its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 1.5% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,989 shares of the company’s stock after selling 93 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in IDEXX Laboratories were worth $3,026,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Crewe Advisors LLC purchased a new stake in shares of IDEXX Laboratories in the 1st quarter valued at about $26,000. Ridgewood Investments LLC acquired a new stake in shares of IDEXX Laboratories in the 2nd quarter worth $27,000. Institutional & Family Asset Management LLC acquired a new stake in IDEXX Laboratories in the second quarter valued at about $28,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of IDEXX Laboratories by 5,700.0% in the third quarter. E Fund Management Hong Kong Co. Ltd. now owns 58 shares of the company’s stock valued at $29,000 after buying an additional 57 shares in the last quarter. Finally, Mowery & Schoenfeld Wealth Management LLC boosted its position in shares of IDEXX Laboratories by 750.0% during the 3rd quarter. Mowery & Schoenfeld Wealth Management LLC now owns 68 shares of the company’s stock worth $34,000 after purchasing an additional 60 shares in the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of several research reports. Piper Sandler reissued a “neutral” rating and issued a $435.00 target price (down previously from $520.00) on shares of IDEXX Laboratories in a report on Monday, November 4th. Barclays lowered their price objective on shares of IDEXX Laboratories from $570.00 to $481.00 and set an “overweight” rating for the company in a research note on Monday, November 4th. BTIG Research started coverage on shares of IDEXX Laboratories in a research report on Thursday, July 25th. They set a “buy” rating and a $580.00 price target on the stock. JPMorgan Chase & Co. reduced their price target on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Finally, Stifel Nicolaus lowered their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating for the company in a research note on Thursday, October 10th. Three investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. Based on data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus target price of $552.38.

IDEXX Laboratories Stock Down 1.4 %

IDXX stock opened at $423.65 on Friday. IDEXX Laboratories, Inc. has a 1 year low of $404.74 and a 1 year high of $583.39. The company has a fifty day simple moving average of $470.26 and a 200 day simple moving average of $483.80. The company has a current ratio of 1.42, a quick ratio of 1.03 and a debt-to-equity ratio of 0.32. The firm has a market cap of $34.69 billion, a PE ratio of 40.85, a PEG ratio of 3.75 and a beta of 1.36.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings results on Thursday, October 31st. The company reported $2.80 earnings per share for the quarter, beating analysts’ consensus estimates of $2.69 by $0.11. IDEXX Laboratories had a net margin of 22.53% and a return on equity of 55.42%. The firm had revenue of $975.50 million during the quarter, compared to the consensus estimate of $980.32 million. During the same period in the prior year, the firm earned $2.53 EPS. The business’s revenue was up 6.6% on a year-over-year basis. Sell-side analysts anticipate that IDEXX Laboratories, Inc. will post 10.43 EPS for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.